Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 8/2017

Open Access 01-08-2017 | Original Article

The relationship between the dopaminergic system and depressive symptoms in cervical dystonia

Authors: E. Zoons, M. A. J. Tijssen, Y. E. M. Dreissen, J. D. Speelman, M. Smit, J. Booij

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 8/2017

Login to get access

Abstract

Purpose

Cervical dystonia (CD) is associated with tremor/jerks (50%) and psychiatric complaints (17–70%). The dopaminergic system has been implicated in the pathophysiology of CD in animal and imaging studies. Dopamine may be related to the motor as well as non-motor symptoms of CD. CD is associated with reduced striatal dopamine D2/3 (D2/3) receptor and increased dopamine transporter (DAT) binding. There are differences in the dopamine system between CD patients with and without jerks/tremor and psychiatric symptoms.

Methods

Patients with CD and healthy controls underwent neurological and psychiatric examinations. Striatal DAT and D2/3 receptor binding were assessed using [123I]FP-CIT and [123I]IBZM SPECT, respectively. The ratio of specific striatal to non-specific binding (binding potential; BPND) was the outcome measure.

Results

Twenty-seven patients with CD and 15 matched controls were included. Nineteen percent of patients fulfilled the criteria for a depression. Striatal DAT BPND was significantly lower in depressed versus non-depressed CD patients. Higher DAT BPND correlated significantly with higher scores on the Unified Myoclonus Rating Scale (UMRS). The striatal D2/3 receptor BPND in CD patients showed a trend towards lower binding compared to controls. The D2/3 BPND was significantly lower in depressed versus non-depressed CD patients. A significant correlation between DAT and D2/3R BPND was found in both in patients and controls.

Conclusions

Alterations of striatal DAT and D2/3 receptor binding in CD patients are related mainly to depression. DAT BPND correlates significantly with scores on the UMRS, suggesting a role for dopamine in the pathophysiology of tremor/jerks in CD.
Literature
1.
2.
3.
Rubio-Agusti I et al. Tremulous cervical dystonia is likely to be familial: clinical characteristics of a large cohort. Parkinsonism Relat Disord. 2013;19(6):634–8.CrossRefPubMedPubMedCentral
4.
5.
Gundel H et al. High psychiatric comorbidity in spasmodic torticollis: a controlled study. J Nerv Ment Dis. 2003;191(7):465–73.CrossRefPubMed
6.
Hess CW et al. Myoclonus-dystonia, obsessive-compulsive disorder, and alcohol dependence in SGCE mutation carriers. Neurology. 2007;68(7):522–4.CrossRefPubMed
7.
Smit M et al. Psychiatric co-morbidity is highly prevalent in idiopathic cervical dystonia and significantly influences health-related quality of life: results of a controlled study. Parkinsonism Relat Disord. 2016;30:7–12.CrossRefPubMed
8.
Di Giuda D et al. Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study. Eur J Nucl Med Mol Imaging. 2012;39(12):1937–48.CrossRefPubMed
9.
Lehn A, Mellick G, Boyle R. Psychiatric disorders in idiopathic-isolated focal dystonia. J Neurol. 2014;261(4):668–74.CrossRefPubMed
10.
Yokoi F et al. Myoclonus, motor deficits, alterations in emotional responses and monoamine metabolism in epsilon-sarcoglycan deficient mice. J Biochem. 2006;140(1):141–6.CrossRefPubMed
11.
12.
Berger HJ et al. Writer’s cramp: restoration of striatal D2-binding after successful biofeedback-based sensorimotor training. Parkinsonism Relat Disord. 2007;13(3):170–3.CrossRefPubMed
13.
Beukers RJ et al. Reduced striatal D2 receptor binding in myoclonus-dystonia. Eur J Nucl Med Mol Imaging. 2009;36(2):269–74.CrossRefPubMed
14.
Horstink CA et al. Low striatal D2 receptor binding as assessed by [123I]IBZM SPECT in patients with writer’s cramp. J Neurol Neurosurg Psychiatry. 1997;62(6):672–3.CrossRefPubMedPubMedCentral
15.
Naumann M et al. Imaging the pre- and postsynaptic side of striatal dopaminergic synapses in idiopathic cervical dystonia: a SPECT study using [123I] epidepride and [123I] beta-CIT. Mov Disord. 1998;13(2):319–23.CrossRefPubMed
16.
Ferris MJ et al. Cocaine self-administration produces pharmacodynamic tolerance: differential effects on the potency of dopamine transporter blockers, releasers, and methylphenidate. Neuropsychopharmacology. 2012;37(7):1708–16.CrossRefPubMedPubMedCentral
17.
Lohr KM et al. Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo. Proc Natl Acad Sci U S A. 2014;111(27):9977–82.CrossRefPubMedPubMedCentral
18.
Anand A et al. Striatal dopamine transporter availability in unmedicated bipolar disorder. Bipolar Disord. 2011;13(4):406–13.CrossRefPubMed
19.
Meyer JH et al. Lower dopamine transporter binding potential in striatum during depression. Neuroreport. 2001;12(18):4121–5.CrossRefPubMed
20.
Vriend C et al. Reduced dopamine transporter binding predates impulse control disorders in Parkinson’s disease. Mov Disord. 2014;29(7):904–11.CrossRefPubMed
21.
Tsui JK et al. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet. 1986;2(8501):245–7.CrossRefPubMed
22.
Booij J, Kemp P. Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging. 2008;35(2):424–38.CrossRefPubMed
23.
Tarsy D. Comparison of clinical rating scales in treatment of cervical dystonia with botulinum toxin. Mov Disord. 1997;12(1):100–2.CrossRefPubMed
24.
Frucht SJ et al. The unified myoclonus rating scale. Adv Neurol. 2002;89:361–76.PubMed
25.
Booij J et al. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson’s disease. J Nucl Med. 1998;39(11):1879–84.PubMed
26.
Booij J, Knol RJ. SPECT imaging of the dopaminergic system in (premotor) Parkinson’s disease. Parkinsonism Relat Disord. 2007;13 Suppl 3:S425–8.CrossRefPubMed
27.
Booij J et al. Assessment of endogenous dopamine release by methylphenidate challenge using iodine-123 iodobenzamide single-photon emission tomography. Eur J Nucl Med. 1997;24(6):674–7.PubMed
28.
Laruelle M et al. SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med. 1995;36(7):1182–90.PubMed
29.
Boot E et al. AMPT-induced monoamine depletion in humans: evaluation of two alternative [123I]IBZM SPECT procedures. Eur J Nucl Med Mol Imaging. 2008;35(7):1350–6.CrossRefPubMedPubMedCentral
30.
Booij J et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;62(2):133–40.CrossRefPubMedPubMedCentral
31.
Koopman KE et al. Assessing the optimal time point for the measurement of extrastriatal serotonin transporter binding with 123I-FP-CIT SPECT in healthy, male subjects. J Nucl Med. 2012;53(7):1087–90.CrossRefPubMed
32.
Figee M et al. Deep brain stimulation induces striatal dopamine release in obsessive-compulsive disorder. Biol Psychiatry. 2014;75(8):647–52.CrossRefPubMed
33.
Innis RB et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27(9):1533–9.CrossRefPubMed
34.
Jakobson Mo S et al. (1)(2)(3)I-FP-Cit and 123I-IBZM SPECT uptake in a prospective normal material analysed with two different semiquantitative image evaluation tools. Nucl Med Commun. 2013;34(10):978–89.CrossRefPubMed
35.
Lavalaye J et al. Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers. Eur J Nucl Med. 2000;27(7):867–9.CrossRefPubMed
36.
Varrone A et al. European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging. 2013;40(2):213–27.CrossRefPubMed
37.
Hierholzer J et al. Dopamine D2 receptor imaging with iodine-123-iodobenzamide SPECT in idiopathic rotational torticollis. J Nucl Med. 1994;35(12):1921–7.PubMed
38.
Gundel H et al. Psychiatric comorbidity in patients with spasmodic dysphonia: a controlled study. J Neurol Neurosurg Psychiatry. 2007;78(12):1398–400.CrossRefPubMedPubMedCentral
39.
Lencer R et al. Primary focal dystonia: evidence for distinct neuropsychiatric and personality profiles. J Neurol Neurosurg Psychiatry. 2009;80(10):1176–9.CrossRefPubMed
40.
Camardese G et al. Changes of dopamine transporter availability in depressed patients with and without anhedonia: a 123I-N-omega-fluoropropyl-carbomethoxy-3beta- (4-Iodophenyl)tropane SPECT study. Neuropsychobiology. 2014;70(4):235–43.CrossRefPubMed
41.
42.
Wu CK et al. No changes in striatal dopamine transporter in antidepressant-treated patients with major depression. Int Clin Psychopharmacol. 2013;28(3):141–4.CrossRefPubMed
43.
Furmark T. Neurobiological aspects of social anxiety disorder. Isr J Psychiatry Relat Sci. 2009;46(1):5–12.PubMed
44.
Schneier FR et al. Dopamine transporters, D2 receptors, and dopamine release in generalized social anxiety disorder. Depress Anxiety. 2009;26(5):411–8.CrossRefPubMedPubMedCentral
45.
Cervenka S et al. Changes in dopamine D2-receptor binding are associated to symptom reduction after psychotherapy in social anxiety disorder. Transl Psychiatry. 2012;2:e120.CrossRefPubMedPubMedCentral
46.
47.
Larisch R et al. In vivo evidence for the involvement of dopamine-D2 receptors in striatum and anterior cingulate gyrus in major depression. Neuroimage. 1997;5(4 Pt 1):251–60.CrossRefPubMed
48.
Hesse S et al. Monoamine transporter availability in Parkinson’s disease patients with or without depression. Eur J Nucl Med Mol Imaging. 2009;36(3):428–35.CrossRefPubMed
49.
50.
Pickett A. Consistent biochemical data are essential for comparability of botulinum toxin type A products. Drugs R&D. 2011;11(1):97–8. author reply 98–9.CrossRef
51.
Dewey SL et al. GABAergic inhibition of endogenous dopamine release measured in vivo with 11C-raclopride and positron emission tomography. J Neurosci. 1992;12(10):3773–80.PubMed
52.
Vilkman H et al. The effects of lorazepam on extrastriatal dopamine D(2/3)-receptors-A double-blind randomized placebo-controlled PET study. Psychiatry Res. 2009;174(2):130–7.CrossRefPubMed
53.
Hou H et al. Decreased striatal dopamine transporters in codeine-containing cough syrup abusers. Drug Alcohol Depend. 2011;118(2–3):148–51.CrossRefPubMed
54.
Liu Y et al. Dopamine transporter availability in heroin-dependent subjects and controls: longitudinal changes during abstinence and the effects of Jitai tablets treatment. Psychopharmacology (Berlin). 2013;230(2):235–44.CrossRef
55.
Yeh TL et al. Availability of dopamine and serotonin transporters in opioid-dependent users--a two-isotope SPECT study. Psychopharmacology (Berl). 2012;220(1):55–64.CrossRef
56.
Zaaijer ER et al. Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients. Psychopharmacology (Berl). 2015;232(14):2597–607.CrossRef
57.
Tsai HY et al. Sunshine-exposure variation of human striatal dopamine D(2)/D(3) receptor availability in healthy volunteers. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(1):107–10.CrossRefPubMed
58.
Yang YK et al. Decreased dopamine transporter availability in male smokers -- a dual isotope SPECT study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(1):274–9.CrossRefPubMed
59.
Thomsen G et al. No difference in striatal dopamine transporter availability between active smokers, ex-smokers and non-smokers using [123I]FP-CIT (DaTSCAN) and SPECT. EJNMMI Res. 2013;3(1):39.CrossRefPubMedPubMedCentral
Metadata
Title
The relationship between the dopaminergic system and depressive symptoms in cervical dystonia
Authors
E. Zoons
M. A. J. Tijssen
Y. E. M. Dreissen
J. D. Speelman
M. Smit
J. Booij
Publication date
01-08-2017
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 8/2017
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-017-3664-x

Other articles of this Issue 8/2017

European Journal of Nuclear Medicine and Molecular Imaging 8/2017 Go to the issue

Editorial

Advanced Hodgkin’s lymphoma: End-of-treatment FDG-PET should be maintained

Original Article

Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients

Original Article

[18F]-FMISO PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis

Original Article

Comparison of CT and PET/CT for biopsy guidance in oncological patients

Reply

“The simplest explanation is usually the correct one” – Can Occam’s razor be applied for diffuse astrocytoma and paradoxical amino acid metabolism?

Original Article

Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer